Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 14 hours ago
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Antoni Chan MD (Prof) synovialjoints
6 days 14 hours ago
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026
Janet Pope Janetbirdope
6 days 14 hours ago
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where new data showcased advances in the field.
sheila RHEUMarampa
6 days 14 hours ago
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Jiha Lee JihaRheum
6 days 14 hours ago
ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. @RheumNow #EULAR2026 POS0255
Bella Mehta bella_mehta
6 days 14 hours ago
Baricitinib inhibits substance P and IL6 - by interfering with the pathway NGF-IL6-SP axis. This is a novel pathway to pain suppression in RA
#EULAR2026 #pos0217 @rheumnow https://t.co/6MsrFH3Mm0
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 14 hours ago
#EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
Bella Mehta bella_mehta
6 days 14 hours ago
Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T
#POS0303 #EULAR2026 @RheumNow
24 months follow up data for 21 pts.
Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy
Mrinalini Dey DrMiniDey
6 days 14 hours ago
#OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
Bella Mehta bella_mehta
6 days 14 hours ago
Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK
Mrinalini Dey DrMiniDey
6 days 14 hours ago
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey DrMiniDey
6 days 14 hours ago
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Bella Mehta bella_mehta
6 days 14 hours ago
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta
6 days 14 hours ago
Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts.
POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV
